Investors

Home / Investors / Overview

Company Information

CymaBay Therapeutics (Nasdaq: CBAY)

We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have two product programs in earlier development that feature unique mechanisms of action and have potential in liver and chronic diseases.

Stock Information


Last Change Volume

Shares Outstanding: 10,064,495
(as of March 3, 2014)

Company Information

CymaBay Therapeutics
7575 Gateway Blvd
Suite 110
Newark, CA 94560

Investor Relations

Sujal Shah
(510) 293-8800
investors@cymabay.com

Recent News

16Nov

CymaBay Therapeutics Announces Oral Late-Breaking Presentation of Positive Results from the ENHANCE Global Phase 3 Study Evaluating Seladelpar for Primary Biliary Cholangitis at The Liver MeetingĀ® 2020

11Nov

CymaBay Therapeutics to Present at Upcoming Investor Conferences

5Nov

CymaBay Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Upcoming Event

Dec 1 2020 3:55 pm ET

Evercore ISI 3rd Annual HealthCONx Conference

December 1, 2020 at 3:55 pm ET

Q3 2020 Quarterly Results